BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

531762

UNJHAFOR

img img img img
No Data Available

UNJHA FORMULATIONS LTD. Share Price Update

As of the latest trading session, UNJHA FORMULATIONS LTD. share price is currently at ₹ 25.2, which is up by ₹ 0.49 from its previous closing. Today, the stock has fluctuated between ₹ 23.52 and ₹ 25.30. Over the past year, UNJHA FORMULATIONS LTD. has achieved a return of -17.66 %. In the last month alone, the return has been 5.19 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

UNJHA FORMULATIONS LTD. fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    11.30

  • P/E Ratio (TTM)

    10.79

  • Beta

    0.55

  • Book Value / share

    9.70

  • Return on equity

    8.77%

  • EPS (TTM)

    2.29

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    0.82

info icon alternate text

UNJHA FORMULATIONS LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 4.29
Operating Expense 3.53
Net Profit 0.82
Net Profit Margin (%) 19.11
Earnings Per Share (EPS) 1.83
EBITDA 0.85
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 3.61
Operating Expense 3.24
Net Profit 0.39
Net Profit Margin (%) 10.80
Earnings Per Share (EPS) 0.90
EBITDA 0.42
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 2.37
Operating Expense 2.73
Net Profit -0.41
Net Profit Margin (%) -17.29
Earnings Per Share (EPS) -0.91
EBITDA -0.26
Effective Tax Rate (%) -41.37
Particulars DEC 2024 (Values in Cr)
Revenue 3.76
Operating Expense 3.55
Net Profit 0.22
Net Profit Margin (%) 5.85
Earnings Per Share (EPS) 0.50
EBITDA 0.24
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 3.78
Operating Expense 3.91
Net Profit -0.11
Net Profit Margin (%) -2.91
Earnings Per Share (EPS) -0.25
EBITDA -0.09
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 13.86
Operating Expense 13.45
Net Profit 0.41
Net Profit Margin (%) 2.95
Earnings Per Share (EPS) 0.91
EBITDA 0.63
Effective Tax Rate (%) 23.07
Particulars MAR 2024 (Values in Cr)
Revenue 18.50
Operating Expense 18.06
Net Profit 0.28
Net Profit Margin (%) 1.51
Earnings Per Share (EPS) 0.62
EBITDA 0.59
Effective Tax Rate (%) 37.77
Particulars MAR 2023 (Values in Cr)
Revenue 13.15
Operating Expense 12.86
Net Profit 0.28
Net Profit Margin (%) 2.12
Earnings Per Share (EPS) 0.63
EBITDA 0.47
Effective Tax Rate (%) 15.15
Particulars MAR 2022 (Values in Cr)
Revenue 14.16
Operating Expense 14.05
Net Profit 0.25
Net Profit Margin (%) 1.76
Earnings Per Share (EPS) 0.56
EBITDA 0.51
Effective Tax Rate (%) 16.66
Particulars MAR 2021 (Values in Cr)
Revenue 9.96
Operating Expense 10.07
Net Profit 0.10
Net Profit Margin (%) 1.00
Earnings Per Share (EPS) 0.23
EBITDA 0.35
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 7.01
ROE % 8.77
ROCE % 11.55
Total Debt to Total Equity 0.00
EBITDA Margin 4.55
Particulars MAR 2024 (Values in Cr)
Book Value / Share 6.10
ROE % 6.00
ROCE % 10.71
Total Debt to Total Equity 0.00
EBITDA Margin 3.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 5.48
ROE % 6.00
ROCE % 8.35
Total Debt to Total Equity 0.00
EBITDA Margin 3.57
Particulars MAR 2022 (Values in Cr)
Book Value / Share 4.84
ROE % 5.35
ROCE % 9.20
Total Debt to Total Equity 0.00
EBITDA Margin 3.60
Particulars MAR 2021 (Values in Cr)
Book Value / Share 4.28
ROE % 2.14
ROCE % 5.78
Total Debt to Total Equity 0.00
EBITDA Margin 3.51
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.64
Total Assets 4.55
Total Liabilities 4.55
Total Equity 3.13
Share Outstanding 4480500
Price to Book Ratio 3.11
Return on Assets (%) 8.94
Return on Capital (%) 12.98
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.87
Total Assets 4.93
Total Liabilities 4.93
Total Equity 2.73
Share Outstanding 4480500
Price to Book Ratio 3.10
Return on Assets (%) 5.63
Return on Capital (%) 10.18
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 3.40
Total Liabilities 3.40
Total Equity 2.45
Share Outstanding 4480500
Price to Book Ratio 2.28
Return on Assets (%) 8.28
Return on Capital (%) 11.52
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.42
Total Assets 3.45
Total Liabilities 3.45
Total Equity 2.17
Share Outstanding 4480500
Price to Book Ratio 1.94
Return on Assets (%) 7.30
Return on Capital (%) 11.63
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.17
Total Assets 3.52
Total Liabilities 3.52
Total Equity 1.91
Share Outstanding 4480500
Price to Book Ratio 1.99
Return on Assets (%) 2.93
Return on Capital (%) 5.4
Particulars MAR 2025 (Values in Cr)
Net Income 0.52
Cash from Operations 0.09
Cash from Investing -0.17
Cash from Financing 0.00
Net change in Cash -0.23
Free Cash Flow 0.28
Particulars MAR 2024 (Values in Cr)
Net Income 0.45
Cash from Operations 1.07
Cash from Investing -0.10
Cash from Financing -0.05
Net change in Cash 0.86
Free Cash Flow 1.18
Particulars MAR 2023 (Values in Cr)
Net Income 0.32
Cash from Operations -0.21
Cash from Investing -0.09
Cash from Financing -0.05
Net change in Cash -0.41
Free Cash Flow -0.10
Particulars MAR 2022 (Values in Cr)
Net Income 0.25
Cash from Operations 0.40
Cash from Investing -0.02
Cash from Financing 0.00
Net change in Cash 0.25
Free Cash Flow 0.43
Particulars MAR 2021 (Values in Cr)
Net Income 0.10
Cash from Operations -0.53
Cash from Investing -0.06
Cash from Financing 0.00
Net change in Cash -0.76
Free Cash Flow -0.46
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.76 13.61 1.44 212.73 27.10 / 68.00
BLISS GVS PHARMA LTD 154.90 14.94 1.44 1637.64 105.05 / 190.65
CIPLA LTD 1508.10 22.39 3.70 121819.98 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 269.45 7.08 2.02 793.02 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2520.20 44.79 25.00 42693.71 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.76 22.57 3.86 212.73 27.10 / 68.00
AMRUTAJAN HEALTH LTD 666.00 33.96 5.62 1925.45 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9089.00 98.29 28.43 22722.50 6301.00 / 10653.05
BLISS GVS PHARMA LTD 154.90 20.90 1.48 1637.64 105.05 / 190.65

UNJHA FORMULATIONS LTD. shareholding pattern

Holding

63.07%
36.92%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

UNJHA FORMULATIONS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
25.19 1.94 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 25.00
  • 26 Days 25.10
  • 10 Days 25.20
  • 50 Days 24.90
  • 12 Days 25.20
  • 100 Days 24.80
  • 20 Days 25.10
  • 200 Days 24.80
25.04 PIVOT

First Support

24.38

First Resistance

25.37

Second Support

24.05

Second Resistance

26.03

Third Support

23.39

Third Resistance

26.36

RSI

46.91

ADX

30.98

MACD

0.08

Williams % R

-67.47

Commodity Channel Index (CCI)

-28.50

Date

2025-12-03

Week

1084.00

Same Day

177.00

Month

3304.00

1 Year

0.56

3 Year

0.27

Over 1 Month

5.19%

down

Over 1 Year

-17.66%

down

Over 3 Months

-1.43%

down

Over 3 Years

33.01%

down

Over 6 Months

3.86%

down

Over 5 Years

27.23%

down

UNJHA FORMULATIONS LTD. Corporate Actions

UNJHA FORMULATIONS LTD. Share Price

Unjha Formulations Ltd was established in Jun.'87 as a partnership firm for manufacturing pharmaceutical formulations in the Mehsana district of Gujarat. It was promoted by Shambhubhai A Patel. The Company is a pioneer in Isabgol (Psyllium) Formulation. The Company is in service to Isabgol (Psyllium) Ayurvedic formulation profession.

The company manufactures pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles, etc. It is one of the largest manufacturers of isabgul products in India. The company's products are classified under two divisions -- human consumption and veterinary products.

Its parent company M/S Urvesh Ltd. is 100% EOU is engaged in exporting of Isabol Husk & Isabgol Powder. The Company is a modern manufacturing plant, having GMP Certificate. It is a manufacturer of all kinds of Small Volume Ayurvedic Isabgol (Psyllium) powder and tested at their plant with their modern & well equipped physico chemical and Micro Biological quality control laboratory.

Company launched four new products viz.Bericof, Protobal-NT, Formentin Tablets and Nalizole in the year 1997-98.

The Company commenced its commercial production and was successfully expanding its customer base throughout the Country including U.P. Territory. Company also interested on development of Export Markets for Ferrous Sulphate, Albendazole Bolus and Iron Folic Tablets to supplement the present law domestic demand situation and achieved export turnover of Rs.0.98 during the year 1997-98.

The Company has made manufacturing agreement with Nicholas Piramal India Limited, Mumbai for sale of Isabgol Husk based Product 'FYBOGEL'.The company received a confirm export order worth Rs.30.00 lacs.

Parent organization Indian Private
NSE symbol [-]
Founded 1994
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Unjha Formulations Ltd?

Answer Field

Unjha Formulations Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 25.19 as on Dec 04 2025 03:04 PM.

What is the Market Cap of Unjha Formulations Ltd Share?

Answer Field

The market cap of Unjha Formulations Ltd for NSE ₹ 0.00 & for BSE ₹ 11.30 as on Dec 04 2025 03:04 PM.

What is the 52 Week High and Low of Unjha Formulations Ltd?

Answer Field

The 52 Week High and Low of Unjha Formulations Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 35.18 and ₹ 19.99.

What is 1 year return for Unjha Formulations Ltd?

Answer Field

The 1 year returns on the stock has been -17.66%.

What is the P/E Ratio of Unjha Formulations Ltd Share?

Answer Field

As on Dec 04 2025 03:04 PM the price-to-earnings (PE) ratio for Unjha Formulations Ltd share is 10.79.

What is the PB ratio of Unjha Formulations Ltd Share?

Answer Field

As on Dec 04 2025 03:04 PM, the price-to-book (PB) ratio for Unjha Formulations Ltd share is 9.70.

How to Buy Unjha Formulations Ltd Share?

Answer Field

You can trade in Unjha Formulations Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Unjha Formulations Ltd Share on Bajaj Broking App?

Answer Field

To buy Unjha Formulations Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Unjha Formulations Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59